For this study, the study medicine has been specially prepared to contain radiolabeled carbon [14C]. [14C] is a naturally occurring radioactive form of the element carbon. Adding a low dose of radiation to the study medicine does not change how the medicine works but helps to see how the medicine appears in the blood, urine, and stool after it is given. This type of study is called a radiolabeled study.

The purpose of this radiolabeled study is to learn how a certain amount of [14C] PF-07248144 is taken up into the bloodstream and removed from the body.

The study is seeking participants who are:

• females who cannot have children, or males
• 18 years of age or older
• confirmed to be healthy based on medical and physical tests.
• weigh more than 50 kilograms (kg) and have a body mass index of 18 to 32 kg per meter squared.

The study consists of two parts. In part one, all participants will receive one full dose of [14C]PF-07248144 by mouth. Part two will begin at least 28 days after the dose in part one. In part two, participants will receive one full dose of PF-07248144 by mouth and one small dose of [14C] PF-07248144 by intravenous (IV) infusion. IV infusion will be directly injected into the veins.

To understand how the medicine is processed in the body, samples of blood, urine, feces, and vomit (if any) will be collected after each dose is given. This will help understand:

• How much PF-07248144 is taken up into the bloodstream when taken by mouth compared to the dose given by IV
• How the body removes it from the blood steam.

Participants will take part in the study for about 15 weeks, including evaluation at the start and follow-up period.

Inclusion Criteria:

• Female of nonchildbearing potential or male ≥18 years of age, inclusive, at screening who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, vital signs, and 12-lead ECGs.
• BMI of 18-32 kg/m2; and a total body weight >50 kg (110 lb).

Exclusion Criteria:

• Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing.
• Previous administration of an investigational product (drug or vaccine) within 30 days or 5 half-lives preceding the first dose of study intervention used in this study (whichever is longer). Participation in studies of other investigational products (drug or vaccine) at any time during participation in this study.
• Total 14C radioactivity measured in plasma should not exceed 2.5 × standard biological carbon ratio.

Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical\_trials/trial\_data\_and\_results/data\_requests.